Chicago Equity Partners LLC Acquires New Position in Bristol-Myers Squibb Company (BMY)

Chicago Equity Partners LLC acquired a new stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 3,710 shares of the biopharmaceutical company’s stock, valued at approximately $207,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tradewinds Capital Management LLC grew its stake in Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares in the last quarter. Blue Chip Partners Inc. grew its stake in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares in the last quarter. American National Bank grew its stake in Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 225 shares in the last quarter. BDO Wealth Advisors LLC purchased a new stake in Bristol-Myers Squibb during the 2nd quarter valued at about $123,000. Finally, Proficio Capital Partners LLC grew its stake in Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 504 shares in the last quarter. 69.51% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Chicago Equity Partners LLC Acquires New Position in Bristol-Myers Squibb Company (BMY)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/18/chicago-equity-partners-llc-acquires-new-position-in-bristol-myers-squibb-company-bmy.html.

Several analysts recently issued reports on the stock. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective for the company. in a research note on Tuesday, August 22nd. Citigroup Inc. set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Thursday, October 26th. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. Finally, Cowen and Company set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $64.93.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.23% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.32 on Friday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a market cap of $101,260.00, a P/E ratio of 20.69, a PEG ratio of 2.42 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. Bristol-Myers Squibb’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 earnings per share. research analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a dividend of $0.39 per share. The ex-dividend date was Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.54%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 61.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply